HCW Biologics Secures $10.2 Million in Notes Financing
HCW Biologics entered into a purchase agreement for $10.2 million in secured notes, closing November 4, 2026. The financing comprises a $3.2 million A-1 Note and a $7.0 million B Note.
HCW Biologics entered into a Notes Purchase Agreement with Streeterville Capital for $10.2 million in secured notes, with closing occurring on November 4, 2026. The financing includes a $3.2 million A-1 Note and a $7.0 million B Note, and the company also engaged Maxim Group as placement agent for…